Drug Profile
Research programme: bi-specific antibody therapeutics - Janssen/Zymeworks
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Zymeworks
- Developer Janssen; Zymeworks
- Class Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified